Literature DB >> 12063293

Role of USF1 phosphorylation on cardiac alpha-myosin heavy chain promoter activity.

Qianxun Xiao1, Agnes Kenessey, Kaie Ojamaa.   

Abstract

Contractile activity of the cardiac myocyte is required for maintaining cell mass and phenotype, including expression of the cardiac-specific alpha-myosin heavy chain (alpha-MHC) gene. An E-box hemodynamic response element (HME) located at position -47 within the alpha-MHC promoter is both necessary and sufficient to confer contractile responsiveness to the gene and has been shown to bind upstream stimulatory factor-1 (USF1). When studied in spontaneously contracting cardiac myocytes, there is enhanced binding of USF1 to the HME compared with quiescent cells, which correlates with a threefold increase in alpha-MHC promoter activity. A molecular mechanism by which contractile function modulates alpha-MHC transcriptional activity may involve signaling via phosphorylation of USF1. The present studies showed that purified rat USF1 was phosphorylated in vitro by protein kinase C (PKC) and cAMP-dependent protein kinase (PKA) but not casein kinase II. Phosphorylated USF1 by either PKC or PKA had increased DNA binding activity to the HME. PKC-mediated phosphorylation also leads to the formation of USF1 multimers as assessed by gel shift assay. Analysis of in vivo phosphorylated nuclear proteins from cultured ventricular myocytes showed that USF1 was phosphorylated, and resolution by two-dimensional gel electrophoresis identified at least two distinct phosphorylated USF1 molecules. These results suggest that endogenous kinases can covalently modify USF1 and provide a potential molecular mechanism by which the contractile stimulus mediates changes in myocyte gene transcription.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063293     DOI: 10.1152/ajpheart.01085.2001

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  8 in total

1.  CMV enhancer may not be suitable for tissue-specific enhancement of promoters in cancer gene therapy.

Authors:  Jing Jia; Shuzhi Zhang; Zhenyu Jia; Jiang Cao
Journal:  Cancer Gene Ther       Date:  2019-05-27       Impact factor: 5.987

2.  Exendin-4 increases histone acetylase activity and reverses epigenetic modifications that silence Pdx1 in the intrauterine growth retarded rat.

Authors:  S E Pinney; L J Jaeckle Santos; Y Han; D A Stoffers; R A Simmons
Journal:  Diabetologia       Date:  2011-07-21       Impact factor: 10.122

3.  Expression characterization and the promoter activity analysis of zebrafish hdac4.

Authors:  Kecheng Zhu; Huanling Wang; Yasmeen Gul; Yuhua Zhao; Weimin Wang; Shasha Liu; Min Wang
Journal:  Fish Physiol Biochem       Date:  2011-07-20       Impact factor: 2.794

4.  Target gene specificity of USF-1 is directed via p38-mediated phosphorylation-dependent acetylation.

Authors:  Sébastien Corre; Aline Primot; Yorann Baron; Jacques Le Seyec; Colin Goding; Marie-Dominique Galibert
Journal:  J Biol Chem       Date:  2009-04-23       Impact factor: 5.157

5.  Upstream stimulatory factor 2 and hypoxia-inducible factor 2α (HIF2α) cooperatively activate HIF2 target genes during hypoxia.

Authors:  Matthew R Pawlus; Liyi Wang; Katie Ware; Cheng-Jun Hu
Journal:  Mol Cell Biol       Date:  2012-09-10       Impact factor: 4.272

6.  Myocyte-specific M-CAT and MEF-1 elements regulate G-protein gamma 3 gene (gamma3) expression in cardiac myocytes.

Authors:  Charlene McWhinney; Janet D Robishaw
Journal:  DNA Cell Biol       Date:  2008-07       Impact factor: 3.311

7.  Protein kinases as switches for the function of upstream stimulatory factors: implications for tissue injury and cancer.

Authors:  Tina Horbach; Claudia Götz; Thomas Kietzmann; Elitsa Y Dimova
Journal:  Front Pharmacol       Date:  2015-02-18       Impact factor: 5.810

8.  GSK3β-dependent phosphorylation alters DNA binding, transactivity and half-life of the transcription factor USF2.

Authors:  Tina Horbach; Tabughang Franklin Chi; Claudia Götz; Satyan Sharma; André H Juffer; Elitsa Y Dimova; Thomas Kietzmann
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.